Literature DB >> 11113845

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.

T G Boyce1, B G Mellen, E F Mitchel, P F Wright, M R Griffin.   

Abstract

OBJECTIVE: To determine rates of hospitalization associated with respiratory syncytial virus (RSV) infection among children with and without specific medical conditions. STUDY
DESIGN: Retrospective cohort study of all children <3 years old enrolled in the Tennessee Medicaid program from July 1989 through June 1993 (248,652 child-years).
RESULTS: During the first year of life, the estimated number of RSV hospitalizations per 1000 children was 388 for those with bronchopulmonary dysplasia, 92 for those with congenital heart disease, 70 for children born at < or = 28 weeks' gestation, 66 for those born at 29 to <33 weeks, 57 for those born at 33 to <36 weeks, and 30 for children born at term with no underlying medical condition. In the second year of life, children with bronchopulmonary dysplasia had an estimated 73 RSV hospitalizations per 1000 children, whereas those with congenital heart disease had 18 and those with prematurity 16 per 1000. Overall, 53% of RSV hospitalizations occurred in healthy children born at term.
CONCLUSIONS: Children with bronchopulmonary dysplasia have high rates of RSV hospitalization until 24 months of age. In contrast, after the first year of life, children with congenital heart disease or prematurity have rates no higher than that of children at low risk who are <12 months old.

Entities:  

Mesh:

Year:  2000        PMID: 11113845     DOI: 10.1067/mpd.2000.110531

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  207 in total

Review 1.  Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

Authors:  Andrew A Colin; Cynthia McEvoy; Robert G Castile
Journal:  Pediatrics       Date:  2010-06-07       Impact factor: 7.124

2.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

3.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

4.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

5.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

6.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

8.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 9.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.

Authors:  A Duppenthaler; R A Ammann; M Gorgievski-Hrisoho; J-P Pfammatter; C Aebi
Journal:  Arch Dis Child       Date:  2004-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.